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A new coronavirus (severe acute respiratory syndrome coronavirus [SARS-CoV]) has been identified to be
the etiological agent of severe acute respiratory syndrome. Given the highly contagious and acute nature of the
disease, there is an urgent need for the development of diagnostic assays that can detect SARS-CoV infection.
For determination of which of the viral proteins encoded by the SARS-CoV genome may be exploited as
diagnostic antigens for serological assays, the viral proteins were expressed individually in mammalian and/or
bacterial cells and tested for reactivity with sera from SARS-CoV-infected patients by Western blot analysis.
A total of 81 sera, including 67 from convalescent patients and seven pairs from two time points of infection,
were analyzed, and all showed immunoreactivity towards the nucleocapsid protein (N). Sera from some of the
patients also showed immunoreactivity to U274 (59 of 81 [73%]), a protein that is unique to SARS-CoV. In
addition, all of the convalescent-phase sera showed immunoreactivity to the spike (S) protein when analyzed
by an immunofluorescence method utilizing mammalian cells stably expressing S. However, samples from the
acute phase (2 to 9 days after the onset of illness) did not react with S, suggesting that antibodies to N may
appear earlier than antibodies to S. Alternatively, this could be due to the difference in the sensitivities of the
two methods. The immunoreactivities to these recombinant viral proteins are highly specific, as sera from 100
healthy donors did not react with any of them. These results suggest that recombinant N, S, and U274 proteins
may be used as antigens for the development of serological assays for SARS-CoV.
The recent severe acute respiratory syndrome (SARS) epi-
demic, which affected over 30 countries, has profoundly dis-
turbed social and economic activities regionally as well as glo-
bally. The high mortality rate of up to 15%, together with the
highly contagious and acute nature of the disease, has imposed
tremendous psychological and economic burden on the public.
In Singapore and elsewhere, to reduce the risk of contact with
people who may have been exposed to the SARS-causing virus,
strict quarantine orders were served to those who had traveled
to SARS-affected countries, those who had been in direct con-
tact with SARS patients, and those with temperatures exceed-
ing 38°C. Early diagnoses of the disease during the early phase
of infection could avoid unnecessary quarantines, reduce the
stress to those concerned, and help doctors to decide on ap-
propriate medical action and/or treatment. It is therefore vital
to identify SARS patients as early as possible, with certainty
and accuracy. Given that no effective anti-SARS therapeutics are
currently available, the first line of defense is to identify and
isolate infected patients as early as possible. Hence, the need
for the development of sensitive and highly specific diagnostic
kits that can be used in the field is urgent and immediate.
A novel coronavirus was identified as the etiological agent of
SARS (2, 3, 5, 10). Coronaviruses are enveloped viruses that
contain a single-stranded, positive-sense RNA genome of 27.6
to 31 kb. Analyses of the nucleotide sequence of the novel
SARS coronavirus (SARS-CoV) showed that the viral genome
is nearly 30 kb in length (9, 11) and contains 14 potential open
reading frames (ORFs) (9). With the identification of the
SARS-CoV genome, several diagnostic tests based on the de-
tection of viral RNA sequences by use of PCR have been
designed and are now available. Such tests, although sensitive,
have inherent problems: scientists and clinicians around the
world are unsure what types of samples (respiratory samples,
saliva, stool, blood, or conjunctival fluid) from patients give the
most reproducible RNA preparations; RNA extraction proto-
cols are not straightforward, and if not done well, may produce
RNA preparations that are not useful for the reverse transcrip-
tion step that converts viral RNA to DNA; and the whole
process of extraction, reverse transcription, and PCR can be
time-consuming if confirmatory tests have to be done with
several pairs of primers. In addition, false positives are possible
with amplification methods, as was observed in August 2003 in
Canada, when some patients infected with other human coro-
naviruses initially tested positive for SARS by a PCR method
(http://www.bccdc.org). Contamination in PCR laboratories is
always a concern, which in the case of SARS could lead to
unnecessary quarantines.
Another commonly used method for the detection of viral
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infections is a serological test that assays for the presence of
antibodies against viral proteins. The sequence of SARS-CoV
reveals ORFs for four structural proteins, i.e., spike (S), mem-
brane (M), envelope (E), and nucleocapsid (N), which are
present in all coronaviruses (6, 9, 11, 13). In addition, there are
several ORFs predicted from the SARS-CoV sequence that
encode proteins unique to SARS-CoV, as they show no signif-
icant sequence homology to viral proteins of other coronavi-
ruses. In this study, we screened a panel of SARS-CoV ORFs
expressed in mammalian and/or bacterial cells for reactivity
toward convalescent-phase patient sera, as well as sera from
acutely infected patients, to determine which antigen(s) would
be most suitable as a diagnostic marker for the detection of
SARS-CoV infection.
MATERIALS AND METHODS
Materials. All reagents used in this study were purchased from Sigma (St.
Louis, Mo.), unless otherwise stated. All cell lines were purchased from the
American Type Culture Collection (Manassas, Va.) and were cultured at 37°C in
5% CO2 in Dulbecco’s modified Eagle medium containing 1 g of glucose/liter, 2
mM L-glutamine, 1.5 g of sodium bicarbonate/liter, 0.1 mM nonessential amino
acids, 0.1 mg of streptomycin/ml, 100 U of penicillin, and 5% fetal bovine serum
(HyClone, South Logan, Utah).
Construction of plasmids. For transient expression in mammalian cells, the
vectors used were pXJ40HA, for tagging proteins at the N terminus with one
hemagglutinin (HA) epitope (8), and pXJ40-3HA, for tagging proteins with
three HA epitopes at the C terminus (T. Leung, Institute of Molecular and Cell
Biology, Singapore, Republic of Singapore, personal communication). For the
expression of glutathione S-transferase (GST) fusion proteins in bacteria, genes
were cloned in frame with GST in pGEX-4T-1 (Amersham Pharmacia Biotech,
Uppsala, Sweden). For the stable transfection of S in CHO cells, a full-length S
construct tagged at the C-terminal end with green fluorescent protein (GFP) was
cloned into the pMMTC vector (14). All of the constructs used for this study are
listed in Table 1.
SARS-CoV 2003VA2774, an isolate from a SARS patient in Singapore, was
used for this study. For the cloning of various genes, RNAs were extracted by use
of a Qiagen viral RNA kit (Valencia, Calif.) from a SARS-CoV-infected Vero E6
cell culture supernatant harvested when the cultures showed at least 75% cyto-
pathic effects. Reverse transcription was performed with Superscript II RNase
H reverse transcriptase (Gibco BRL, Gaithersburg, Md.) and an oligo(dT)
primer. PCRs were performed with either HotStar polymerase (Qiagen), Tita-
nium Taq DNA polymerase (Clontech Laboratories Inc., Palo Alto, Calif.), or
High Fidelity Taq polymerase (Roche Molecular Biochemicals, Indianapolis,
Ind.). In some cases, overlapping cDNAs provided by the Genome Institute of
Singapore (isolate SIN2774; accession no. AY283798 [12]) were used as tem-
plates instead.
All of the primers used for this study were synthesized by Genset Singapore
Biotech (Singapore). The sequences of all constructs used in this study were
confirmed by DNA sequencing performed at the core facility at the Institute of
Molecular and Cell Biology by the dideoxy method with a Taq DyeDeoxy ter-
minator cycle sequencing kit and an automated DNA sequencer (model 373)
from PE Applied Biosystems (Foster City, Calif.).
Transient transfection of mammalian cells. Transient transfection experi-
ments were performed with Effectene transfection reagent (Qiagen) according to
the manufacturer’s protocol. Typically, 106 COS-7 cells were plated on a
6-cm-diameter dish and allowed to attach for at least 4 h. One to 2 g of DNA
was used per plate, and the cells were left for at least 14 h before the cells were
washed with phosphate-buffered saline (PBS), lysed directly in Laemmli’s sodium
dodecyl sulfate (SDS) buffer, and used for Western blot analysis.
Expression of GST fusion proteins. Exponentially growing cultures (optical
density at 600 nm of 0.7) of Escherichia coli (BL21/DE3) cells harboring the
pGEX-4T-1 expression constructs were induced to synthesize fusion proteins by
the addition of 1 mM isopropyl--D-thiogalactopyranoside (IPTG), after which
the cells were allowed to grow for another 4 h at 37°C or 12 h at 30°C. Cells were
harvested, resuspended in PBS containing 0.5% Triton X-100 and 1 mM phe-
nylmethylsulfonyl fluoride, and then sonicated with an ultrasonic processor (Mi-
sonix Inc., Farmingdale, N.Y.). GST fusion proteins were then purified from the
lysate by use of glutathione (GSH)-Sepharose beads (Amersham Pharmacia
Biotech). Proteins were eluted from the beads with 10 mM reduced GSH in 50
mM Tris-HCl, pH 9.2, and 0.1% SDS, and protein concentrations were deter-
mined by use of a Coomassie Plus assay kit (Pierce, Rockford, Ill.). Proteins were
also separated in SDS-polyacrylamide gels and stained with 0.25% Coomassie
brilliant blue R-250 (Bio-Rad, Hercules, Calif.) in 45% methanol and 10% acetic
acid.
Western blot analysis. For Western blot analysis, approximately 105 trans-
fected COS-7 cells or 50 ng of GST fusion proteins was separated in SDS-
polyacrylamide gels and transferred to nitrocellulose Hybond C membranes
(Amersham Pharmacia Biotech). The membranes were blocked with 5% nonfat
dry milk. For the detection of HA-tagged or GST fusion proteins, the mem-
branes were incubated with either an anti-HA polyclonal or anti-GST monoclo-
nal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) overnight at 4°C and
washed extensively with PBST (PBS containing 0.05% Tween 20), followed by
incubation with an appropriate horseradish peroxidase (HRP)-conjugated sec-
ondary antibody (Pierce) for 1 h at room temperature. Membranes were then
washed extensively with PBST, and the detection of signals by an enhanced
chemiluminescence method (Pierce) was performed. For patient sera, each sam-
ple was first treated with 0.5% Triton X-100 and 0.1 mg of RNase (Sigma)/ml and
then diluted 1:150 to 1:500 with PBST containing 1% nonfat dry milk. After
incubation for 1 to 3 h at room temperature or overnight at 4°C, the membranes
were incubated with an anti-human HRP-conjugated immunoglobulin G (IgG)
(Santa Cruz Biochemicals), IgA, or IgM (Zymed Laboratories Inc., San Fran-
cisco, Calif.) antibody for 1 h at room temperature, followed by detection as
described above. All secondary antibodies were used at a 1:2,000 dilution. Due
to the limited amount of patient sera from the seven pairs of sera, Western blots
of a mixture of three GST fusion proteins, N, U274, and U122, and GST were
run in a single-slot SDS–10% polyacrylamide gel electrophoresis (PAGE) gel
and transferred onto nitrocellulose membranes. The membranes were cut into
strips of about 0.8 mm wide, and each strip was probed with 300 to 400 l of
diluted sera. For the late time point sera, the strips were incubated with the
diluted sera for 1.5 h at room temperature. For the early time point sera, the
strips had to be incubated overnight with the sera, at room temperature, to detect
any signal. The secondary antibodies were incubated for 1 h at room tempera-
ture. This method was also used when large numbers of samples were being
screened.
Expression of S-GFP fusion protein in CHO cells and immunofluorescence
analysis to determine anti-S immunoreactivity in patient sera. CHO cells were
transfected with pMMTC-S-GFP by use of DMRIE-C reagent (Gibco BRL)
according to the manufacturer’s protocol. Transfected cells were selected in
Geneticin (Gibco BRL) for 1 week. Cells were then analyzed under a Zeiss
microscope (Carl Zeiss Vision GmbH, Hallbergmoss, Germany), and the clone
with the strongest expression signal was picked and grown in medium containing
100 M ZnSO4. Zn2 ions increase the expression of genes by the pMMTC
vector (14).
Cells were dislodged from the plates with 0.04% EDTA, seeded onto black
Teflon Menzel diagnostic slides (Merck), and blown dry, followed by fixing in
acetone at 20°C for 1 h. Then the cells were incubated with sera at dilutions of
1:20, 1:40, 1:80, and 1:160 (in PBS) for 1.5 h at 37°C, followed by incubation with
a fluorescein isothiocyanate (FITC)- or rhodamine (Rh)-conjugated anti-human
IgG (Sigma) at a 1:20 dilution for 1.5 h at 37°C. When Rh-conjugated anti-
human IgG was used, it was diluted in PBS, and when FITC-conjugated anti-
human IgG, IgM (Sigma), or IgA (Dako A/S, Glostrup, Denmark) was used, it
was diluted in 0.05% Evans Blue solution (Fluka, Buchs, Switerland), which
blocks GFP fluorescence from transfected cells. Slides were then viewed under a
Zeiss microscope (Carl Zeiss Vision GmbH) and scored as follows: , very
strong staining; , moderate staining; and , weak staining.
Collection of sera from SARS-CoV-infected patients. The first six serum sam-
ples (from patients 1 to 6), except for that from patient 3, were obtained by
TABLE 1. Plasmids used for this study





pXJ40HA-U274 400–822 134–274 141
pXJ40-E-3HA 1–228 1–76 76
pXJ40-M-3HA 1–663 1–221 221
pXJ40-U122-3HA 1–366 1–122 122
pXJ40HA-N 203–1266 69–422 354
pMMTC-S-GFP 1–3765 1–1255 1,255
pGEX-4T1-U274 400–822 134–274 141
pGEX-4T1-U122 46–333 16–111 96
pGEX-4T1-N 357–1266 120–422 303
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plasmapheresis. Plasmapheresis was performed on patients who (i) had previous
documented SARS-CoV infection according to World Health Organization
(WHO) criteria, (ii) had been in the convalescent phase for at least 6 weeks, and
(iii) were symptom-free and willing to participate in the study. Blood was taken
from patient 3, and the serum was separated out for the experiments. All
participants have given written consent, and approval from the Tan Tock Seng
Hospital Ethics Committee has been granted.
The second set of sera consisted of seven pairs of samples that were collected
from patients admitted to Tan Tock Seng Hospital or Singapore General Hos-
pital. These patients were admitted upon the onset of illness, as defined by WHO
criteria, and the dates of admission and dates of collection of blood are shown in
Table 2. The first samples (set A) were collected 2 to 11 days after the onset of
illness, and the second set of samples (set B) were collected 16 to 54 days after
the onset of illness.
The last set of sera was obtained from 61 probable SARS patients who were
discharged from Tan Tock Seng Hospital. For some of these patients, sera were
taken upon discharge (3 to 4 weeks after the onset of illness), while most of the
patients were recruited 3 weeks after discharge (6 weeks after the onset of
illness) (see Table 3 for details). For one patient (patient P3L), a serum sample
was taken 111 days (3 1/2 months) after the onset of illness. Samples from two
other patients (P7 and P8) were obtained by plasmapheresis.
A control serum was purchased from Sigma, and 99 serum samples were
obtained from healthy donors who have given informed consent. These healthy
donors (i) did not have a diagnosis of SARS, suspect SARS, or have contact with
a person who was served a home quarantine order for SARS; (ii) did not have a
fever, symptoms of influenza, runny nose, or sore throat within the last week at
the time of donation; (iii) had not been on immunosuppressants; (iv) had no
significant medical illnesses; and (v) had no history of travel to SARS-affected
areas since November 2002.
RESULTS
Detection of IgG antibodies against viral proteins encoded
by the SARS-CoV genome in the sera of probable SARS pa-
tients. In order to assess which of the viral proteins encoded by
the SARS-CoV genome may be exploited as diagnostic anti-
gens for the development of a serological assay to detect
SARS-CoV infection, we cloned three of the four structural
proteins (E, M, and N) into expression vectors. Due to the
large size (4.7 kbp) and heavy glycosylation of the spike (S)
protein, it was analyzed separately by an immunofluorescence
method (see below). In addition, two of the SARS-CoV unique
proteins (U274 and U122) were also included in this study, and
they will be referred to hereafter as UX, where “X” stands for
the number of predicted amino acids of the proteins. In this
study, we used only the C-terminal hydrophilic region of U274,
as it has three potential transmembrane domains at its N-ter-
minal end and these hydrophobic regions may affect the solu-
bility of a recombinant U274 protein. The positions of the struc-
tural and unique proteins and their corresponding ORF numbers,
as designated by Marra and coworkers (9), are shown in Fig. 1a.
This panel of HA-tagged proteins was expressed in COS-7
cells by transient transfection, and total protein lysates were
analyzed by Western blot analysis with sera from three conva-
lescent patients (Fig. 1b, patients 1 to 3) to determine if these
sera had any antibodies against the expressed proteins. Plas-
mapheresis was performed on patients 1 and 2, and the plasma-
pheresis products were used in Western blot analysis, while for
patient 3, serum was used for the analysis. All three patients had
antibodies against the N (amino acids [aa] 69 to 422) protein,
but not against the other structural proteins, M and E. Interest-
ingly, the C-terminal hydrophilic region of U274 (aa 134 to 274)
was also detected by the sera of patients 1 and 3 but not by the
serum of patient 2 (Fig. 1b). A control serum did not detect N,
U274, or any other proteins. U122 was also not detected by any
of the three sera, suggesting that it may not be expressed, it is
not a structural protein, or it is not sufficiently antigenic.
As bacterially expressed proteins are easier and cheaper to
produce on a large scale, we next expressed N and U274 as
GST fusion proteins and tested them for reactivity to patient
sera. Coomassie staining showed that GST-N (aa 120 to 422)
and GST-U274 (aa 134 to 274) were of 90% purity after a
one-step purification with GSH-Sepharose beads (Fig. 2a).
The GST-N (aa 120 to 422) protein used here lacked the
N-terminal part of the N protein, which contains a highly
conserved motif (FYYLGTGP; aa 111 to 118 of SARS-CoV
N) found in all coronaviruses (11), so there would be less
chance of cross-reactivity with antibodies against other coro-
naviruses. From a 400-ml bacterial culture, 10 mg of GST-N
and 2 mg of GST-U274 could be obtained, respectively.
GST-U122 (aa 16 to 111) (lacking the signal peptide at the N
terminus and the hydrophobic C terminus) and GST were also
expressed and used as controls. The GST fusion proteins were
probed with the same three patient sera and one control se-
rum, as for the mammalian expressed proteins (Fig. 1b). Con-
sistent with the proteins expressed in COS-7 cells, GST-N was
clearly detected by all three patient sera and GST-U274 was
detected only by the sera from patients 1 and 3 (Fig. 2b).
Neither GST-U122 nor GST showed any background with all
three patient sera, and there was no nonspecific binding of the
control serum to any of the proteins (Fig. 2b). Sera from
another three convalescent patients (patients 4 to 6) were also
tested, and they were reactive specifically towards both GST-N
and GST-U274, but not to GST-U122 or GST (Fig. 2b).
Profile of IgG, IgM, and IgA antibodies against N and U274
proteins in seven pairs of sera obtained at two time points of
infection. A set of paired sera from seven patients were also
examined for reactivity against GST-N and GST-U274. These
were obtained at two time points of infection, one at 2 to 11
days after the onset of illness (set A) and another at 16 to 54
days after the onset of illness (set B) (Table 2). For all seven
cases, the second time point samples were taken at least 8 days
after the first time point samples. As shown in Fig. 3a, anti-IgG
antibodies against GST-N protein were present in all seven
patients’ sera at the later time point (set B), but not at the early
time points (set A). For both sets of sera, the membranes were
incubated with the diluted sera (1:150) for 1.5 h at room
temperature, followed by incubation with the secondary anti-
TABLE 2. Description of sera collected from seven SARS-CoV-
infected patients at two different time points
Patient Sample Date of onsetof illness
Date of sample
collection
No. of days after
onset of illness
D2 2A 18 March 2003 20 March 2003 2
2B 18 March 2003 15 April 2003 28
D3 3A 17 March 2003 20 March 2003 3
3B 17 March 2003 17 April 2003 31
D4 4A 16 March 2003 20 March 2003 4
4B 16 March 2003 31 May 2003 48
D5 5A 2 April 2003 7 April 2003 5
5B 2 April 2003 29 April 2003 27
D8 8A 19 March 2003 27 March 2003 8
8B 19 March 2003 4 April 2003 16
D9 9A 9 March 2003 18 March 2003 9
9B 9 March 2003 2 May 2003 54
D11 11A 24 February 2003 7 March 2003 11
11B 24 February 2003 3 April 2003 38
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body (HRP-conjugated anti-human IgG) for 1 h at room tem-
perature. In addition, all seven of the late time point sera also
contained antibodies against GST-U274, albeit at a lower level
than that for GST-N (Fig. 3a, set B).
We repeated the experiment for the early time point sera
(set A) but incubated the blots with diluted sera overnight at
room temperature instead of for 1.5 h and used three different
secondary antibodies, anti-IgG, anti-IgM, and anti-IgA, and
the results for each of them are shown in Fig. 3b. For IgG, only
samples 9A and 11A showed some reactivity to GST-N. For
IgA, though, all seven samples showed reactivity to GST-N,
and the signals were particularly strong for samples 9A and
11A. For IgM, all seven samples showed a low level of reac-
tivity to GST-N. As the early time point sample for each pa-
tient was collected a different number of days after the onset of
illness, our results suggest that by as early as 2 days after the
onset of illness (patient D2, sample 2A), IgM and IgA anti-
bodies against the N protein were present. By 9 days after the
onset of illness, very high levels of IgA antibodies against N
were present and IgM and IgG antibodies were also detectable
(Fig. 3b, samples 9A and 11A). As for GST-U274, some reac-
tivities were observed for IgA (samples 5A, 8A, 9A, and 11A)
and for IgM (sample 11A) from 5 to 11 days after the onset of
illness. Interestingly, quite a strong signal for GST-U274 was
observed for sample 11A (11 days after the onset of illness)
when IgM was used, and for the corresponding early sample,
11B, the signal for GST-U274 was also strong (Fig. 3).
Determination of the sensitivity and specificity of immuno-
reactivity (IgG) against N and U274 proteins. In order to
determine the sensitivity and specificity of the immunoreactiv-
TABLE 3. Reactivities of serum samples collected from 74 probable SARS patients 16 to 111 days after the onset of illness against N,



















No. of days after
onset of illnessc
174    49
318    53
350    62
358    60
377    61
387    63
432    42
442    63
487    54
492    31
526    63
541    58
546    62
561    57
566    59
571    57
576    63
581    53
586    38
596    39
603    67
621    50
633    39
638    60
644    41
672    53
677    59
682    58
687    61
696    41
701    40
706    39
711    54
716    40
726    34
734    41
739    49
744    68
a Determined by Western blot analysis. , , , very strong, moderate, and weak signals, respectively, were observed on the autoradiograph; , no signal was
observed.
b Determined by an immunofluorescence method in which CHO cells stably expressing the S protein were incubated with a diluted patient serum (1:40) followed
by a FITC-conjugated anti-human IgG antibody. Slides were then viewed under a Zeiss microscope and scored as follows: , very strong staining; , moderate
staining; , weak staining. One hundred sera from healthy volunteers were examined at the same dilution, and none of them showed any staining.
c Samples were obtained at the stated number of days after the onset of illness.
d Samples from two healthy contacts (patients 868 and 873) were also examined.
e Samples obtained by plasmapheresis.
f Late time point from one of the seven pairs of sera described in Table 2.
749    59
759    42
764    43
769    64
774    62
784    38
789    55
793    48
798    44
803    40
823    37
840    43
845    36
859    55
868d    Not applicable
873d    Not applicable
878    58
883    56
888    33
893    41
4153    41
4209    21
P3L    111
P1e    42
P2e    42
P3    42
P4e    42
P5e    42
P6e    42
P7e    42
P8e    42
2Bf    28
3Bf    31
4Bf    48
5Bf    27
8Bf    16
9Bf    54
11Bf    38
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ity against N and U274, we obtained another 61 samples from
probable SARS patients who were discharged from hospitals
and tested them for the presence of IgG antibodies against N
and U274 by Western blot analysis. As shown in Table 3, the
samples were taken from 31 to 111 days after the onset of
illness. Plasmapheresis products from 2 of the patients (P7 and
P8) and sera from the other 59 patients were used. All of the
samples showed strong immunoreactivity against the N protein
(100%), and 44 of the 61 samples (72%) were positive for
U274 (Table 3). In general, the signals observed for the U274
protein were much lower than those for the N protein. The
exceptions were samples from patients 749 and 859, for which
the signals for the U274 and N proteins were equally strong.
Another 99 samples from healthy donors were also tested, and
none of them showed any immunoreactivity to N or U274. In
addition, samples from two patients (patients 868 and 873)
who had close contact with probable SARS patients but never
developed any of the clinical symptoms also did not show any
immunoreactivity to N or U274 (Table 3). Therefore, the im-
munoreactivity against the N protein is highly sensitive (found
in 100% of a total of 81 samples from probable SARS patients)
and specific.
Detection of IgG antibodies against SARS-CoV S protein in
convalescent-phase sera by immunofluorescence. Due to the
large size and heavy glycosylation of the S protein, it is advan-
tageous to express this protein in mammalian cells instead of
bacteria, as it is then possible to detect antibodies that may be
dependent on conformation and/or glycosylation of the S pro-
tein. CHO cells were stably transfected with a full-length S
construct tagged at the C-terminal end with GFP. After selec-
tion with antibiotics, a pool of clones expressing significant
levels of S protein, as indicated by GFP fluorescence, were
obtained (Fig. 4). These CHO cells were used for an immu-
nofluorescence staining method to determine if there were IgG
antibodies against the SARS-CoV S protein in convalescent-
phase sera. Briefly, the cells were fixed with acetone and then
incubated with diluted patient sera, followed by incubation
with an Rh-conjugated anti-human IgG antibody. As shown in
Fig. 4, sera from patients 1 to 6 all contained IgG antibodies
against S, as detected by immunofluorescence, and no signal
was observed when a control serum was used.
All remaining samples were tested similarly, except that the
Rh-conjugated anti-human IgG antibody was replaced with a
FITC-conjugated one in the presence of a high concentration
of Evans Blue solution (0.05%). This is because of the greater
ease of judging cells stained with FITC than those stained with
Rh, and this concentration of Evans Blue solution was suffi-
cient to block out all of the GFP fluorescence in the trans-
fected cells (data not shown). As shown in Table 3, 100% of the
convalescent-phase sera (74 samples) showed immunoreactiv-
ity against S at a dilution of 1:40, and 100 samples from healthy
donors did not show any signal at the same dilution. The lowest
FIG. 1. Structural organization and expression of ORFs of SARS-CoV. (a) ORFs corresponding to structural proteins S, M, N, and E and
unique proteins (UX) and corresponding annotated ORFs (1 to 14) are indicated. “X” denotes the number of amino acids encoded by the
respective ORF. (b) Western blot analysis to determine the presence of antibodies against the various SARS-CoV viral proteins in patient sera.
HA-tagged proteins were expressed in mammalian cells and probed with anti-HA antibody, antibodies in a control serum, or antibodies in three
convalescent-phase sera (patients 1 to 3).
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dilution tested was 1:20, but a few of the samples from healthy
donors showed weak signals at this concentration; therefore,
the results from the 1:40 dilution were used for comparison. At
higher dilutions (1:80 and 1:160), weaker signals were observed
for most of the patient sera, as would be expected. In partic-
ular, for samples 432, 633, 784, 840, 878, 893, 3B, 5B, and 8B,
for which very strong signals () were observed at a 1:40
dilution, the signals decreased gradually at higher dilutions,
i.e., moderate signals () were observed at 1:80 and weak
signals () were observed at 1:160.
FIG. 2. Expression and detection of bacterially expressed viral proteins with convalescent-phase patient sera. (a) GST-U274, GST-U122,
GST-N, and GST proteins were expressed in bacteria and purified with GSH-Sepharose beads. Proteins were analyzed by SDS-PAGE and stained
with Coomassie brilliant blue R-250 (Bio-Rad). Bovine serum albumin (BSA) standards were also run in the same gel. (b) These proteins
(approximately 150 ng of each) were separated by SDS-PAGE and subjected to Western blot analysis with an anti-GST antibody, antibodies in
a control serum, or antibodies in six convalescent-phase sera (patients 1 to 6).
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The seven early time point samples (Table 2, set A) were
also analyzed in the same manner, but with IgG, IgM, and IgA
secondary antibodies separately, but none of them showed any
reactivity (at a 1:40 dilution) (data not shown).
DISCUSSION
The sequence of SARS-CoV reveals ORFs for four struc-
tural proteins, i.e., S, M, E, and N, which are present in all
coronaviruses (6, 9, 11, 13). The S protein plays essential roles
in mediating receptor binding and internalization of the virus
and is one of the major antigens of the virus. The M and
E proteins are essential for virion assembly, and the N
protein binds to the viral genome to form the nucleocapsid.
Besides these four common structural proteins, there are sev-
eral unique ORFs predicted from the SARS-CoV sequence.
Whether these ORFs are expressed or not and whether the
expressed proteins serve a function in the viral replication cycle
are yet to be determined.
We first screened a panel of ORFs expressed in mammalian
and bacterial cells for reactivity towards convalescent-phase
patient sera. As shown in Fig. 1b and 2b, the N protein was
found to have strong immunoreactivity (IgG) with six of the
convalescent-phase sera tested. Further tests using seven pairs
FIG. 3. Detection of N and U274 with sera from patients during early and late phases of infection. (a) Reactivity to GST-N and GST-U274 was
determined with sera from seven pairs of samples. Set A represents samples from an early time point (2 to 11 days after the onset of illness) and
set B represents samples collected at a later time point (16 to 54 days after the onset of illness). GST fusion proteins were transferred to
nitrocellulose membranes, and the membranes were incubated with diluted sera for 1.5 h at room temperature, followed by incubation with an
HRP-conjugated anti-human IgG secondary antibody for 1 h at room temperature. (b) Samples from set A were reexamined by using three
different secondary antibodies, namely anti-human IgG, anti-human IgA, or anti-human IgM antibody. The membranes were incubated with
diluted sera overnight at room temperature followed by incubation with the respective secondary antibody for 1 h at room temperature.
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FIG. 4. Detection of anti-S antibodies in patient sera by an immunofluorescence method utilizing mammalian cells stably expressing the S pro-
tein. Pools of CHO cells which were stably transfected with a full-length S construct tagged at the C-terminal end with GFP showed GFP fluorescence
(GFP panel). These cells were fixed and incubated with control or patient sera (diluted 1:40), followed by an Rh-conjugated anti-human IgG
antibody. Cells incubated with all patient sera (patients 1 to 6) showed strong staining, but no staining was seen when a control serum was used.
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of sera from patients also showed that high levels of IgG
antibodies against the N protein were present at later time
points (16 to 54 days) (Table 2) for all samples (Fig. 3a, set B).
For the early time points (set A), there were lower levels of
IgG and IgM antibodies against N, but for two of the patients,
D9 and D11, the IgA antibodies against N were present at high
levels (Fig. 3b, samples 9A and 11A). As the early time point
serum from patient D9 (sample 9A) was taken at day 9 after
the onset of illness, the data suggest that a high level of IgA
antibodies against N can be present by this time. Taken to-
gether, all seven early samples (set A) showed immunoreac-
tivities to the N protein, and one of the samples was taken as
early as 2 days after the onset of illness (sample 2A). Finally, a
third set of 61 samples from convalescent patients was 100%
positive for IgG antibodies against N (Table 3). These samples
were collected from 31 to 111 days after the onset of illness,
and the high level of IgG antibodies against N observed here is
consistent with a recent report that IgG antibodies against
SARS-CoV in patients persisted for 13 weeks after the onset
of symptoms (7). The presence of a strong immunoreactivity
towards N suggests that it may be released from the virus or
infected cells into the circulation at some stage of infection or
that it may be presented by antigen-presenting cells for cyto-
toxic killing of infected cells. We therefore speculate that IgG
antibody against N may contribute to the humoral immune
response protecting patients against SARS, as has been ob-
served for other coronaviruses (13). Future experiments will
aim to address the mechanism by which N is presented as an
antigen and its role in viral infection and/or replication. Our
results also complement the preliminary mass spectrometric
identification of N as the most immunogenic viral antigen (4).
Interestingly, unlike some coronaviruses in which the M pro-
tein is most abundant, N appears to be the most abundant
protein in SARS-CoV (11).
As may be expected, 100% (74 of 74) of the convalescent-
phase sera also showed reactivity to the large S glycoprotein,
which is responsible for the petal-shaped spikes found on the
surfaces of coronaviruses (6, 13). In this case, we used full-
length S expressed in mammalian cells (CHO) to achieve
proper folding and glycosylation of the protein and immuno-
fluorescence techniques for analysis. This has some advantages
over immunofluorescence using SARS-CoV-infected Vero
cells, as the latter would require a biosafety level 3 facility.
However, this method still needs specialized expertise and is
labor-intensive and thus not suited to mass testing. Therefore,
in future studies, it is important to determine the epitope(s) on
the S protein that is recognized by the antibodies in patient
sera, as this epitope(s) may be easier to express than the
full-length S protein and may allow the development of chro-
matographic or enzyme-linked immunosorbent assay (ELISA)-
based diagnostic assays.
In addition, we also found that the majority of the patients
(59 of 81 [73%]) had antibodies against the C-terminal end of
U274 (corresponding to ORF 3, as annotated in reference 9,
and X1 in reference 11), a protein unique to SARS-CoV. The
immunoreactivity of U274 indicates that this novel and unique
viral protein is expressed and is likely to be a protein involved
in the biogenesis of SARS-CoV. Moreover, a potential tran-
scription regulating sequence was found upstream of the U274
coding sequence, suggesting that it is the first ORF for one of
the major subgenomic RNAs of SARS-CoV-infected cells (9,
11). U274 does not share any significant homology with any
protein in the database, but it appears to have a similar topol-
ogy to that of M, with three transmembrane regions and a large
internal C-terminal domain. It would be interesting to unravel
the function of U274. The patients in this study showed differ-
ential response to N and U274, and it is important to deter-
mine in future studies if this difference correlates with any
significant clinical parameters.
With the identification of S, N, and U274 as antigenic pro-
teins, diagnostic tests can be developed to detect the presence
of antibodies against these proteins in suspected patients. Be-
cause of the fact that early-phase sera of all seven patients
showed immunoreactivity to N, IgA and/or IgM offers a pow-
erful and reliable system for the diagnosis of early infection. In
addition, the presence of high levels of IgG antibodies against
these proteins, in particular the N protein, in late infection or
convalescent-phase sera suggests that this system would also be
suitable for epidemiological studies. Further studies of sequen-
tially bled patients in early stages of infection will be needed to
characterize the development of these antibodies over time,
and consequently, their utility in early infection. The N and
U274 proteins can easily be expressed in bacteria and may be
purified to a high degree, which might provide a better sensi-
tivity and specificity over the current use of coarse viral lysates
for serological assays, as the presence of antibodies against
cellular components in viral lysates can result in false positivity.
Therefore, the use of these recombinant viral antigens in a
rapid chromatographic or ELISA-based kit can be expected to
yield a superior diagnostic test. Due to the difficulty of express-
ing the S protein, the N protein appears to be the best candi-
date for the development of serological assays for the rapid
detection of SARS-CoV infection. Indeed, the recombinant
proteins S and U274 described here have been shown to work
well in an ELISA format (3a).
It is still not clear whether SARS-CoV undergoes a high rate
of genetic mutation, although some differences have been ob-
served between the viral genomes sequenced so far (for exam-
ples, see references 1, 12, and 15). However, the S protein is
predicted to contain hypervariable regions, as these have been
found in other coronaviruses (6, 13), and this might pose an-
other problem for the use of S in diagnostic assays. For the N
protein, when we compared the sequences of 18 SARS isolates
that were deposited in the GenBank database, we found that
only two of them showed a difference, at one amino acid, from
that of the Singapore isolate (SIN2774) that we used for this
study (data not shown; also see reference 12). Therefore, the N
protein does not appear to undergo rapid mutation, which is
another advantage for its use for serological assay develop-
ment. For U274, there is a slightly larger variance between the
different reported sequences, with five sequences showing one
amino acid substitution (when compared to SIN2774) and one
sequence showing two amino acid substitutions (1). This may
be one reason why fewer of the patient sera (73% compared to
100% for the N protein) reacted with the recombinant U274
protein used here.
This study is the first to dissect the range of antibody re-
sponses against SARS-CoV during infection. In summary, we
have shown that antibodies against the S and N proteins are
present in convalescent-phase sera from patients fulfilling the
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WHO case definition of probable SARS but not in sera from
healthy contacts or volunteers. This observation is consistent
with the finding that SARS-CoV is the causative agent of
SARS. The analysis of seven pairs of sera showed that lower
levels of antibodies (mainly IgM and IgA) against N were
present during the acute phase of infection and that high levels
of IgG antibodies were detected after 16 days or more. To
date, serological diagnosis for SARS has been the most reliable
method, but it requires convalescent-phase serum collected 28
days after the onset of illness to be the most accurate (http:
//www.cdc.gov/ncidod/sars/testresultsc.htm) and is thus retro-
spective. Our data showed that IgM and/or IgA assays could
help in early diagnosis. Although Li and coworkers (7) re-
ported that patients were positive for IgM only from week 2 of
illness (when assayed with coarse viral lysates), the use of
recombinant N protein may increase the sensitivity of ELISA
assays and allow for earlier detection.
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